PD-L1 Antibody from MYBIOSOURCE INC.
Search, find, compare suppliers for anti-PD-L1 antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | PD-L1 |
| Clone | [IHC411] |
| Host Species | Rabbit |
| Reactive Species | human |
| Isotype | n/a |
| Format | unconjugated |
| Size | 0.1 mL (Concentrate), 7 mL (Prediluted), 1 mL (Concentrate) |
| Concentration | n/a |
| Applications | n/a |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | Intended Use: The PD-L1 [IHC411] antibody is intended for qualified laboratories to qualitatively identify by light microscopy the presence of associated antigens in sections of formalin-fixed, paraffin-embedded tissue sections using IHC test methods. Description: Programmed Death-Ligand 1 (PD-L1), also known as CD274 or B7 Homolog 1 (B7-H1), is a transmembrane protein involved in suppressing the immune system and rendering tumor cells resistant to CD8+ T cell-mediated lysis through binding of the Programmed Death-1 (PD-1) receptor. Overexpression of PD-L1 may allow cancer cells to evade the actions of the host immune system. In renal cell carcinoma, upregulation of PD-L1 has been linked to increased tumor aggressiveness and risk of death, |
| Immunogen | n/a |
| Other Names | [programmed cell death 1 ligand 1 isoform c; Programmed cell death 1 ligand 1; programmed cell death 1 ligand 1; CD274 molecule; B7 homolog 11, [CD274; CD274; B7-H; B7H1; PDL1; PD-L1; PDCD1L1; PDCD1LG1; PD-L12 PublicationsManual assertion based on opinion iniRef.10; PDCD1 ligand 1; Programmed death ligand 1; B7-H11 |
| Gene, Accession # | [PD-L1], Gene ID: 29126, NCBI: NP_001300958.1 |
| Catalog # | MBS344033 |
| Price | $155, $200, $285 |
| Order / More Info | PD-L1 Antibody from MYBIOSOURCE INC. |
| Product Specific References | 1. Ostrand-Rosenberg S, et al. J Immunol. 2014; 193:3835-41.2. Tokito T, et al. Eur J Cancer. 2016; 55:7-14.3. Park IH, et al. Clin Breast Cancer. 2016; 16:51-8.4. Kakavand H, et al. Mod Pathol. 2015; 28: 1535-44.5. Xia B, et al. Immunotherapy. 2016; 8:279-98.6. Patel SP, et al. Mol Cancer Ther. 2015; 14:847-56.7. Singh BP, et al. Cancers (Basel). 2016; 8.8. Chemnitz JM, et al. J Immunol. 2004; 173:945-54.9. Thompson RH, et al. Proc Natl Acad Sci USA. 2004; 101:17174-9.10. Hamanishi J, et al. Proc Natl Acad Sci USA. 2007; 104:3360-5.11. Mozaffarian N, et al. Rheumatology, 2008; 47:1335-41. |
MYBIOSOURCE INC.
MYBIOSOURCE INC.
P.O. Box 153308
San Diego CA 92195-3308
P: 1.858.633.0165
P: 1.888.MBS.0165 (1.888.627.0165) (US & Canada)
F: 1.858.633.0166
sales@mybiosource.com
http://www.MyBioSource.com
Profile of MYBIOSOURCE INC.
Return to Antibodies